← ANALYST RATINGS · TIPRANKS
Corvus Pharmaceuticals (CRVS): analyst forecast and price target
Analyst consensus
Strong Buy4 Buy0 Hold0 Sell
Ratings of 4 analysts in the last 3 months12-month forecast
Based on 4 price targets given in the last 3 months, the average target is $29.50, the highest $33.00, the lowest $27.00. The average is +209.9% from the last price of $9.52.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $11.00 → $9.50−13.6% | Hold | −0.2% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $11.00 → $9.50−13.6% | Hold | −0.2% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $10.50 → $9.50−9.5% | Hold | −0.2% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $10.50 → $9.00−14.3% | Hold | −5.5% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $11.00 → $9.50−13.6% | Hold | −0.2% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $10.50 → $9.00−14.3% | Hold | −5.5% | Reiterated | 14.10.26on TipRanks 10:05 | — | |
| Graig Suvannavejh★★★★★★★★★★#381 · hits 48% · avg +21.6% | Mizuho Securities | $30.00 | Buy | +215.1% | Reiterated | 11.08.26on TipRanks 15:30 | +7.5%next day +1.9% · 5 days +1.1% | ↗ |
| Sean Lee CFA★★★★★★★★★★#10658 · hits 30% · avg −1.5% | H.C. Wainwright | $27.00 | Buy | +183.6% | Reiterated | 10.08.26on TipRanks 06:35 | −1.3%next day +7.5% · 5 days +8.6% | ↗ |
| Jeff Jones★★★★★★★★★★#749 · hits 46% · avg +20.3% | Oppenheimer | $33.00 | Buy | +246.6% | Reiterated | 07.08.26on TipRanks 10:08 | −0.2%next day −1.3% · 5 days +6.6% | ↗ |
| Etzer Darout★★★★★★★★★★#105 · hits 63% · avg +31.4% | Barclays | $28.00 | Buy | +194.1% | Reiterated | 07.08.26on TipRanks 04:19 | −0.2%next day −1.3% · 5 days +6.6% | ↗ |
| Paul Choi★★★★★★★★★★#1415 · hits 56% · avg +9.6% | Goldman Sachs | $40.00 | Buy | +320.2% | Reiterated | 14.05.26on TipRanks May 15 07:50 | −14.6%next day −8.6% · 5 days −3.5% | ↗ |
| Roger Song★★★★★★★★★★#4779 · hits 41% · avg +2.6% | Jefferies | $13.00 → $42.00+223.1% | Buy | +341.2% | Reiterated | 22.01.26on TipRanks 12:35 | +14.7%next day −1.7% · 5 days −18.7% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Corvus Pharmaceuticals
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $29.50 at a price of $11.52 (+156.1%); now: $29.50 at $9.52 (+209.9%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 14 | 11 | 11 | 6 | 5 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 29.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.19 (from $-0.23 to $-0.11). Last quarter: $-0.19.
Best top-analyst consensus in the sector · Healthcare
About Corvus Pharmaceuticals
- CEO: Richard A. Miller
- Employees: 37
- 901 Gateway Boulevard, South San Francisco, CA, 94080, US
- www.corvuspharma.com
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, is in Phase II clinical trials for individuals diagnosed with either advanced or refractory renal cell carcinoma. Beyond these clinical-stage assets, Corvus maintains a preclinical portfolio including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. The company also benefits from a strategic collaboration with Angel Pharmaceuticals, which aids in advancing its diverse pipeline of targeted experimental drugs. Founded in 2014, Corvus Pharmaceuticals is headquartered in Burlingame, California.
Data from the stock’s TipRanks forecast page, read 54 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗